14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Elevation of MMP-9 Levels Promotes Epileptogenesis After Traumatic Brain Injury

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Posttraumatic epilepsy (PTE) is a recurrent seizure disorder that often develops secondary to traumatic brain injury (TBI) that is caused by an external mechanical force. Recent evidence shows that the brain extracellular matrix plays a major role in the remodeling of neuronal connections after injury. One of the proteases that is presumably responsible for this process is matrix metalloproteinase-9 (MMP-9). The levels of MMP-9 are elevated in rodent brain tissue and human blood samples after TBI. However, no studies have described the influence of MMP-9 on the development of PTE. The present study used controlled cortical impact (CCI) as a mouse model of TBI. We examined the detailed kinetics of MMP-9 levels for 1 month after TBI and observed two peaks after injury (30 min and 6 h after injury). We tested the hypothesis that high levels of MMP-9 predispose individuals to the development of PTE, and MMP-9 inhibition would protect against PTE. We used transgenic animals with either MMP-9 knockout or MMP-9 overexpression. MMP-9 overexpression increased the number of mice that exhibited TBI-induced spontaneous seizures, and MMP-9 knockout decreased the appearance of seizures. We also evaluated changes in responsiveness to a single dose of the chemoconvulsant pentylenetetrazol. MMP-9-overexpressing mice exhibited a significantly shorter latency between pentylenetetrazol administration and the first epileptiform spike. MMP-9 knockout mice exhibited the opposite response profile. Finally, we found that the occurrence of PTE was correlated with the size of the lesion after injury. Overall, our data emphasize the contribution of MMP-9 to TBI-induced structural and physiological alterations in brain circuitry that may lead to the development of PTE.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Glutamate and GABA imbalance following traumatic brain injury.

          Traumatic brain injury (TBI) leads to multiple short- and long-term changes in neuronal circuits that ultimately conclude with an imbalance of cortical excitation and inhibition. Changes in neurotransmitter concentrations, receptor populations, and specific cell survival are important contributing factors. Many of these changes occur gradually, which may explain the vulnerability of the brain to multiple mild impacts, alterations in neuroplasticity, and delays in the presentation of posttraumatic epilepsy. In this review, we provide an overview of normal glutamate and GABA homeostasis and describe acute, subacute, and chronic changes that follow injury. We conclude by highlighting opportunities for therapeutic interventions in this paradigm.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.

            Matrix metalloproteinase-9 (MMP-9) is a member of the metzincin family of mostly extracellularly operating proteases. Despite the fact that all of these enzymes might be target promiscuous, with largely overlapping catalogs of potential substrates, MMP-9 has recently emerged as a major and apparently unique player in brain physiology and pathology. The specificity of MMP-9 may arise from its very local and time-restricted actions, even when released in the brain from cells of various types, including neurons, glia, and leukocytes. In fact, the quantity of MMP-9 is very low in the naive brain, but it is markedly activated at the levels of enzymatic activity, protein abundance, and gene expression following various physiological stimuli and pathological insults. Neuronal MMP-9 participates in synaptic plasticity by controlling the shape of dendritic spines and function of excitatory synapses, thus playing a pivotal role in learning, memory, and cortical plasticity. When improperly unleashed, MMP-9 contributes to a large variety of brain disorders, including epilepsy, schizophrenia, autism spectrum disorder, brain injury, stroke, neurodegeneration, pain, brain tumors, etc. The foremost mechanism of action of MMP-9 in brain disorders appears to be its involvement in immune/inflammation responses that are related to the enzyme's ability to process and activate various cytokines and chemokines, as well as its contribution to blood-brain barrier disruption, facilitating the extravasation of leukocytes into brain parenchyma. However, another emerging possibility (i.e., the control of MMP-9 over synaptic plasticity) should not be neglected. The translational potential of MMP-9 has already been recognized in both the diagnosis and treatment domains. The most striking translational aspect may be the discovery of MMP-9 up-regulation in a mouse model of Fragile X syndrome, quickly followed by human studies and promising clinical trials that have sought to inhibit MMP-9. With regard to diagnosis, suggestions have been made to use MMP-9 alone or combined with tissue inhibitor of matrix metalloproteinase-1 or brain-derived neurotrophic factor as disease biomarkers. MMP-9, through cleavage of specific target proteins, plays a major role in synaptic plasticity and neuroinflammation, and by those virtues contributes to brain physiology and a host of neurological and psychiatric disorders. This article is part of the 60th Anniversary special issue.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Synaptic circuit remodelling by matrix metalloproteinases in health and disease.

              J Huntley (2012)
              Matrix metalloproteinases (MMPs) are extracellularly acting enzymes that have long been known to have deleterious roles in brain injury and disease. In particular, widespread and protracted MMP activity can contribute to neuronal loss and synaptic dysfunction. However, recent studies show that rapid and focal MMP-mediated proteolysis proactively drives synaptic structural and functional remodelling that is crucial for ongoing cognitive processes. Deficits in synaptic remodelling are associated with psychiatric and neurological disorders, and aberrant MMP expression or function may contribute to the molecular mechanisms underlying these deficits. This Review explores the paradigm shift in our understanding of the contribution of MMPs to normal and abnormal synaptic plasticity and function.
                Bookmark

                Author and article information

                Contributors
                +48 22 589 23 82 , b.pijet@nencki.gov.pl
                +48 22 589 23 82 , m.stefaniuk@nencki.gov.pl
                +48 22 589 23 56 , a.kostrzewska@nencki.gov.pl
                +1 612-467-1466 , tsili001@umn.edu
                +30 210 650 3678 , atzin@bio.demokritos.gr
                +48 22 589 22 40 , l.kaczmarek@nencki.gov.pl
                Journal
                Mol Neurobiol
                Mol. Neurobiol
                Molecular Neurobiology
                Springer US (New York )
                0893-7648
                1559-1182
                17 April 2018
                17 April 2018
                2018
                : 55
                : 12
                : 9294-9306
                Affiliations
                [1 ]ISNI 0000 0001 1943 2944, GRID grid.419305.a, Laboratory of Neurobiology, Department of Molecular and Cellular Neurobiology, , Nencki Institute of Experimental Biology, ; Pasteura 3, 02-093 Warsaw, Poland
                [2 ]ISNI 0000000419368657, GRID grid.17635.36, Department of Neuroscience, , University of Minnesota, ; Minneapolis, MN 55405 USA
                [3 ]Brain Sciences Center, Minneapolis, MN 55417 USA
                [4 ]ISNI 0000 0004 0635 6999, GRID grid.6083.d, Laboratory of Cell and Matrix Pathobiology, Institute of Bioscience and Applications, , NCSR Demokritos, ; 153 10 Aghia Paraskevi Attikis, Athens, Greece
                Author information
                http://orcid.org/0000-0002-9268-5208
                Article
                1061
                10.1007/s12035-018-1061-5
                6208832
                29667129
                2c5b7524-c701-41d3-bc97-58360dc85797
                © The Author(s) 2018

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 6 December 2017
                : 3 April 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100005632, National Center of Research and Development (NCBiR);
                Award ID: NEURON/09/13
                Award Recipient :
                Funded by: National Center of Research and Development (NCBiR)
                Award ID: PBS/A8/36/2015
                Award Recipient :
                Categories
                Article
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2018

                Neurosciences
                traumatic brain injury,controlled cortical impact,matrix metalloproteinase-9 (mmp-9),extracellular matrix (ecm),epileptogenesis,posttraumatic epilepsy

                Comments

                Comment on this article